Literature DB >> 8224145

Effect of different endothelin receptor antagonists and of the novel non-peptide antagonist Ro 46-2005 on endothelin levels in rat plasma.

B M Löffler1, V Breu, M Clozel.   

Abstract

The goal of our study was to evaluate and compare the effects of receptor blockade with different endothelin (ET) receptor antagonists on plasma concentrations of ET-1, big ET-1 and ET-3 in conscious rats. Ro 46-2005 10 mg/kg, i.v.), a novel non-peptide antagonist of both ETA and ETB receptors, increased the concentrations of ET-1 in plasma to 200 +/- 13% of basal levels (P < 0.001). This effect was dose- and time-dependent and reached a maximum at 15 min. Ro 46-2005 had no effect on plasma concentrations of big ET-1 and only a minor effect on those of ET-3. In contrast to Ro 46-2005, the selective peptide ETA antagonists BQ-123 and FR-139317 had no effect on plasma ET-1 concentrations. The increase in plasma ET-1 concentrations by Ro 46-2005 was most likely not due to de novo synthesis, since big ET-1 levels were not increased and peak levels were reached early after compound injection, but perhaps to displacement of ET-1 from the ETB receptors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8224145     DOI: 10.1016/0014-5793(93)80384-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  13 in total

Review 1.  Regulation of blood pressure and salt homeostasis by endothelin.

Authors:  Donald E Kohan; Noreen F Rossi; Edward W Inscho; David M Pollock
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

2.  The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044.

Authors:  C Plumpton; C J Ferro; W G Haynes; D J Webb; A P Davenport
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

Review 3.  ET-1 actions in the kidney: evidence for sex differences.

Authors:  W Kittikulsuth; J C Sullivan; D M Pollock
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

4.  Bosentan-improved cardiopulmonary vascular performance and increased plasma levels of endothelin-1 in porcine endotoxin shock.

Authors:  E Weitzberg; A Hemsén; A Rudehill; A Modin; M Wanecek; J M Lundberg
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

5.  Chronic blockade of endothelin A and B receptors using macitentan in experimental renovascular disease.

Authors:  Nathan A Tullos; Nicholas J Stewart; Ryan Davidovich; Alejandro R Chade
Journal:  Nephrol Dial Transplant       Date:  2014-11-21       Impact factor: 5.992

6.  Pharmacokinetics and pharmacodynamic effects of ABT-627, an oral ETA selective endothelin antagonist, in humans.

Authors:  M C Verhaar; A Y Grahn; A W Van Weerdt; M L Honing; P J Morrison; Y P Yang; R J Padley; T J Rabelink
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

7.  Gene expression of endothelin-1 and endothelin receptor a on monocrotaline-induced pulmonary hypertension in rats after bosentan treatment.

Authors:  Kyoung Ah Lim; Kwan Chang Kim; Min-Sun Cho; Bo En Lee; Hae Soon Kim; Young Mi Hong
Journal:  Korean Circ J       Date:  2010-09-30       Impact factor: 3.243

8.  The endothelin receptor antagonist bosentan restores gut oxygen delivery and reverses intestinal mucosal acidosis in porcine endotoxin shock.

Authors:  A Oldner; M Wanecek; M Goiny; E Weitzberg; A Rudehill; K Alving; A Sollevi
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

9.  Antihypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats.

Authors:  E L Schiffrin; P Sventek; J S Li; A Turgeon; T Reudelhuber
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

10.  Paracrine renal endothelin system in rats with liver cirrhosis.

Authors:  B Hocher; R Zart; F Diekmann; P Rohmeiss; A Distler; H H Neumayer; C Bauer; P Gross
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.